S. et al. from 11 randomized controlled trials of PARPi in BRCA1/2-mutated populations, including ovarian, breast, pancreatic and prostate cancer, was performed to assess the efficacy difference of PARPi between BRCA1 and BRCA2 mutation carriers. This evidence concerns the gene BRCA1 and prostate carcinoma.